Thousands of women who tested negative for breast and ovarian cancer gene mutations decades ago are now being urged to undergo genetic retesting. According to The Washington Post, rapid advances since the early 2000s mean early panels missed critical variants, leaving many patients unaware of their true hereditary risk.
Why Are Women Who Tested Negative Decades Ago Now Being Urged to Get Retested?
Medical technology has evolved at a staggering pace since screening for breast cancer mutations first began in 1996 with tests focused strictly on the BRCA1 and BRCA2 genes. Back then, Tricia James was 27 years old when she underwent genetic testing due to a strong family history of breast and ovarian cancer alongside ovarian cysts.
When she got tested again, the same gene variation considered in 1996 came back positive. Retesting had never been suggested in the intervening years, leaving her completely blindsided by the diagnosis.
And I prayed that they would be negative, and they were.
Experts warn that James is far from alone in her experience. There are probably thousands of individuals out there who need to be retested,
she stated.
How Much Has Genetic Screening Technology Advanced Since the Late 1990s?
Doctors recommend this screening when specific factors indicate a higher risk, such as a family history of cancer.
While early technology fell short in detecting certain variants, she pointed out that we’ve made rapid, profound advances in our genetic testing since the early 2000s.
Identifying such variations provides a woman with a more complete understanding of her risk, significantly increasing the odds of both breast and ovarian cancers.
What Caused the Shift Toward Comprehensive Panel Testing?
However, everything changed legally and commercially in 2013. The Supreme Court overturned Myriad’s patent that year, ruling that genomic DNA could not be patented.
The revolution of panel testing began,
Merajver said, describing how other companies quickly entered the market to offer testing for additional genes linked to a higher-than-average risk of breast and gynecologic cancers.
Siddhartha Yadav, an associate professor of oncology at the Mayo Clinic, noted that these results added to the growing body of evidence
supporting retesting, especially given the extensive panels now available.
What Obstacles Still Prevent Patients From Seeking Updated Screenings?
Despite the clear medical benefits, significant barriers remain. Yadav is concerned that too few doctors are explaining this to their patients.
By the time [patients] come to me, it’s too late to talk about prevention,
Yadav said.
The 2023 study identified distinct hurdles to retesting, starting with cost, because health insurance may not always cover it. Logistics also play a major role: Women who think they are in the clear do not regularly see an oncologist.
She was retested for 37 mutations in 2025 after getting cancer in her other breast. The result came back positive for BRCA1.
I was shocked,
she said. I didn’t even think that they were testing me for BRCA.
Her cancer is now in remission, and she has embraced a new role as an advocate.
Don’t be afraid of it,
she said. Get ahead of it because knowledge is going to make the difference.
Worth a look
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.